A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE PHARMACOKINETICS OF PF-06700841 FOLLOWING SINGLE ORAL ADMINISTRATION OF MODIFIED RELEASE TABLETS COMPARED TO IMMEDIATE RELEASE TABLETS UNDER FASTED CONDITIONS
Phase of Trial: Phase I
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Brepocitinib (Primary)
- Indications Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 May 2019 Status changed from recruiting to completed.
- 25 Feb 2019 Planned End Date changed from 14 Feb 2019 to 3 Apr 2019.
- 25 Feb 2019 Planned primary completion date changed from 14 Feb 2019 to 3 Apr 2019.